FSTL1 aggravates OVA-induced allergic airway inflammation by activating NLRP3 inflammasome

Yan Wang, Tian Liu, Junfei Wang, Bao‐yi Liu, Jinxiang Wu, Jiping Zhao, Shuo Li, Jiawei Xu, Lili Cao, Jintao Zhang, Liang DongResearch 2020 · DOI

Asthma remains a significant global health challenge, affecting nearly 18% of the population. Characterized by chronic airway inflammation, mucus hypersecretion, and airway hyper-responsiveness (AHR), the disease's underlying molecular mechanisms are still being unraveled. While standard therapies provide relief for many, a subset of patients requires more targeted interventions. Recent research has highlighted Follistatin-like protein 1 (FSTL1) as a potential mediator in inflammatory disorders. This study investigates the role of FSTL1 in allergic airway inflammation and its interaction with the NLRP3 inflammasome.

Clinical Evidence: FSTL1 and IL-1β in Asthma

The study first examined the clinical relevance of FSTL1 by analyzing serum samples from 30 asthmatic patients and 30 healthy controls. The results revealed that both FSTL1 and Interleukin-1β (IL-1β) levels were significantly elevated in the asthmatic group. Notably, a strong positive correlation was found between circulating FSTL1 and IL-1β levels (r = 0.749, P < 0.0001), suggesting that FSTL1 may drive the production of this potent inflammatory cytokine in asthma.

Figure 1: FSTL1 levels correlate with IL-1β in asthma patients and its deficiency attenuates airway inflammation in mice.

Experimental Validation in Mouse Models

To determine if FSTL1 is actively involved in disease progression, researchers utilized an Ovalbumin (OVA)-induced asthma model in mice. They compared wild-type (WT) mice with $Fstl1^{+/-}$ heterozygous mice, which have reduced FSTL1 expression.

The findings were striking: FSTL1 deficiency significantly ameliorated the hallmarks of asthma. $Fstl1^{+/-}$ mice exhibited:

  • Reduced Airway Hyper-responsiveness: Lower lung resistance (RL) compared to WT mice after allergen exposure.
  • Decreased Inflammatory Infiltration: A significant reduction in the number of eosinophils and other inflammatory cells in the bronchoalveolar lavage fluid (BALF).
  • Less Tissue Damage: Histological analysis (H&E and PAS staining) showed reduced inflammatory cell infiltration around the airways and decreased mucus production in the lungs of $Fstl1^{+/-}$ mice.
  • Lower Cytokine Levels: Reduced levels of Th2-associated cytokines, including IL-5 and IL-13, in the BALF.

The NLRP3 Inflammasome Mechanism

The study further explored the molecular pathway through which FSTL1 exerts its effects. The NLRP3 inflammasome is a multi-protein complex that, when activated, triggers the cleavage of pro-caspase-1 into its active form, leading to the maturation and release of IL-1β.

In vitro experiments using primary peritoneal macrophages showed that FSTL1 stimulation increased NLRP3 expression in a dose-dependent manner. Furthermore, FSTL1 promoted the self-cleavage of pro-caspase-1. The importance of this pathway was confirmed using MCC950, a selective NLRP3 inhibitor, which successfully blocked FSTL1-induced inflammasome activation and attenuated airway inflammation both in vivo and in vitro.

Conclusion and Therapeutic Potential

This research identifies FSTL1 as a pro-inflammatory molecule in the context of asthma, rather than the cardioprotective role it plays in other tissues. By activating the NLRP3 inflammasome, FSTL1 triggers a cascade of inflammatory signals that exacerbate airway symptoms. These findings suggest that targeting the FSTL1-NLRP3 axis could offer a novel therapeutic strategy for patients with allergic airway inflammation, particularly those who do not respond adequately to current standard treatments.

Future studies are needed to identify the specific receptors involved in FSTL1 uptake and to determine if these findings apply across different asthma phenotypes.

Summary updated

Abstract

Abstract Background Asthma is a common respiratory disease characterized by chronic airway inflammation. As a novel inflammatory mediator, follistatin-like protein 1 (FSTL1) can activate immune reaction, suggesting that it may contribute to inflammatory disorders such as asthma. Besides, there are growing evidences that nucleotide-binding domain and leucine-rich repeat protein 3 (NLRP3) / Interleukin (IL)-1β axis participates in asthma. In this study, we investigated the role of FSTL1 in allergic airway inflammation and its underlying mechanism of activating NLRP3 inflammasome. Methods Circulating FSTL1 and IL-1β levels were quantified in serum of asthmatic patients and controls. Whole-body ablation Fstl1 heterozygous mice (Fstl1 +/- ) and control group were assessed after the experimental treatment. The effects of FSTL1 on NLRP3 inflammasome were also tested in primary macrophages of mice in vitro. Results The concentration of FSTL1 and IL-1β in serum of asthmatic patients were elevated compared with controls and were positively correlated. FSTL1 deficiency ameliorated infiltration of inflammatory cells,corresponding pathological changes,cytokine responses (IL-1β, IL-5,IL-13), mucous hypersecretion and hyper-responsiveness of airway after Ovalbumin (OVA) exposure in the mouse model. Additionally, inhibition of NLRP3 with MCC950 attenuated FSTL1-induced activation of NLRP3 inflammasome and airway inflammation in vivo and vitro. Conclusions Our data showed that FSTL1 played an important role in allergic airway inflammation by activating NLRP3 inflammasome, providing the possibility that FSTL1 could be applied as a therapeutic strategy on asthma.
BibTeX
@inproceedings{wang2020fstl,
  author = {Yan Wang and Tian Liu and Junfei Wang and Bao‐yi Liu and Jinxiang Wu and Jiping Zhao and Shuo Li and Jiawei Xu and Lili Cao and Jintao Zhang and Liang Dong},
  title = {{FSTL1 aggravates OVA-induced allergic airway inflammation by activating NLRP3 inflammasome}},
  booktitle = {Research},
  year = {2020},
  doi = {10.21203/rs.3.rs-19657/v1},
}
Figure